Aksoy F, Gokce E, Balkan E, Dundar H, Kaya E
Turk J Surg. 2025; 40(4):267-274.
PMID: 39980646
PMC: 11831993.
DOI: 10.47717/turkjsurg.2024.6474.
Cohen-Nowak A, Hill V, Kumthekar P
Cancers (Basel). 2024; 16(21).
PMID: 39518124
PMC: 11545036.
DOI: 10.3390/cancers16213686.
Tang L, Zhang W, Chen L
Breast Cancer (Dove Med Press). 2024; 16:379-392.
PMID: 39071808
PMC: 11278000.
DOI: 10.2147/BCTT.S460856.
Wilcox J, Chukwueke U, Ahn M, Aizer A, Bale T, Brandsma D
Neuro Oncol. 2024; 26(10):1781-1804.
PMID: 38902944
PMC: 11449070.
DOI: 10.1093/neuonc/noae103.
Esquea E, Ciraku L, Young R, Merzy J, Talarico A, Ahmed N
Front Pharmacol. 2024; 15:1394685.
PMID: 38818373
PMC: 11137182.
DOI: 10.3389/fphar.2024.1394685.
Differential Distribution of Brain Metastases from Non-Small Cell Lung Cancer Based on Mutation Status.
Chen B, Jin T, Ye N, Chen S, Rockne R, Yoon S
Brain Sci. 2023; 13(7).
PMID: 37508989
PMC: 10377121.
DOI: 10.3390/brainsci13071057.
Risk of metastasis in BRCA2 carriers diagnosed with triple-negative breast cancer.
Moreno M, Oliveira J, Brianese R, Guedes de Castro D, Sanches S, Torrezan G
Cancer Med. 2023; 12(15):16129-16141.
PMID: 37485802
PMC: 10469712.
DOI: 10.1002/cam4.6267.
Immunotherapy: an emerging modality to checkmate brain metastasis.
Ahmad A, Khan P, Rehman A, Batra S, Nasser M
Mol Cancer. 2023; 22(1):111.
PMID: 37454123
PMC: 10349473.
DOI: 10.1186/s12943-023-01818-7.
Development and external validation of a prediction model for brain metastases in patients with metastatic breast cancer.
Wu Q, Sun M, Liu Y, Ye J, Xu L
J Cancer Res Clin Oncol. 2023; 149(13):12333-12353.
PMID: 37432458
DOI: 10.1007/s00432-023-05125-y.
Anatomical Targeting of Anticancer Drugs to Solid Tumors Using Specific Administration Routes: Review.
Saito A, Kitayama J, Nagai R, Aizawa K
Pharmaceutics. 2023; 15(6).
PMID: 37376112
PMC: 10301590.
DOI: 10.3390/pharmaceutics15061664.
TME-targeted approaches of brain metastases and its clinical therapeutic evidence.
Khan I, Ullah Khan S, Sala H, Khan M, Azhar Ud Din M, Khan S
Front Immunol. 2023; 14:1131874.
PMID: 37228619
PMC: 10204080.
DOI: 10.3389/fimmu.2023.1131874.
Breast cancer brain metastases localization and risk of hydrocephalus: a single institution experience.
Travers S, Fisher C, Kabos P, Cittelly D, Ormond D
J Neurooncol. 2023; 163(1):115-121.
PMID: 37131107
DOI: 10.1007/s11060-023-04314-6.
Epidemiological trends, prognostic factors, and survival outcomes of synchronous brain metastases from 2015 to 2019: a population-based study.
Parker M, Jiang K, Rincon-Torroella J, Materi J, Azad T, Kamson D
Neurooncol Adv. 2023; 5(1):vdad015.
PMID: 36968289
PMC: 10034914.
DOI: 10.1093/noajnl/vdad015.
Systematic review of the management of brain metastases from hormone receptor positive breast cancer.
Jusino S, Fadul C, Dillon P
J Neurooncol. 2023; 162(1):45-57.
PMID: 36884200
PMC: 10049940.
DOI: 10.1007/s11060-023-04276-9.
Radiosurgery of limited brain metastases from primary solid tumor: results of the randomized phase III trial (NCT02355613) comparing treatments executed with a specialized or a C-arm linac-based platform.
Scorsetti M, Navarria P, Cozzi L, Clerici E, Bellu L, Franceschini D
Radiat Oncol. 2023; 18(1):28.
PMID: 36750848
PMC: 9906937.
DOI: 10.1186/s13014-023-02216-5.
Meningeal carcinomatosis secondary to neurenteric cysts with malignant transformation: a case report.
Chu M, Wang L, Ye H, Li J, Lu D, Piao Y
BMC Neurol. 2022; 22(1):433.
PMID: 36384561
PMC: 9667666.
DOI: 10.1186/s12883-022-02978-7.
Recent Trends in Synchronous Brain Metastasis Incidence and Mortality in the United States: Ten-Year Multicenter Experience.
Che W, Liu J, Fu T, Wang X, Lyu J
Curr Oncol. 2022; 29(11):8374-8389.
PMID: 36354720
PMC: 9689090.
DOI: 10.3390/curroncol29110660.
Management of Brain Metastases from Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Cancer.
McGranahan T, Bonm A, Specht J, Venur V, Lo S
Cancers (Basel). 2022; 14(20).
PMID: 36291922
PMC: 9601150.
DOI: 10.3390/cancers14205136.
Radiotherapy for Leptomeningeal Carcinomatosis in Breast Cancer Patients: A Narrative Review.
Pawlowska E, Romanowska A, Jassem J
Cancers (Basel). 2022; 14(16).
PMID: 36010893
PMC: 9405891.
DOI: 10.3390/cancers14163899.
Risk Factors of Brain Metastasis and Prognosis in HER2-Positive Breast Cancer: A Single-Institution Retrospective Analysis from China.
Cai S, Wang Z, Chen X, Han L, Gong G, Chen Y
Front Oncol. 2022; 12:905065.
PMID: 35832552
PMC: 9271963.
DOI: 10.3389/fonc.2022.905065.